Ohira Masahiro, Ohdan Hideki, Mitsuta Hiroshi, Ishiyama Kohei, Tanaka Yuka, Igarashi Yuka, Asahara Toshimasa
Department of Surgery, Division of Frontier Medical Science, Programs for Biomedical Research, Graduate School of Biomedical Science, Hiroshima University, Hiroshima, Japan.
Transplantation. 2006 Dec 27;82(12):1712-9. doi: 10.1097/01.tp.0000250935.41034.2d.
Antitumor activity of the liver natural killer (NK) cells reportedly decreases after partial hepatectomy, suggesting that patients with such depressed immune status are susceptible to the recurrence of hepatocellular carcinoma (HCC). We hypothesize that adoptive immunotherapy using activated NK cells can be a novel strategy to improve the depressed immune status in patients with HCC after hepatectomy or partial liver transplantation. In the present study, we have tested this hypothesis by using a mouse model.
Intraportal injection of 1-5 x 10(6) Hepa1-6 cells (hepatoma cell line) did not result in liver metastases in untreated B6 mice, but led to the growth of liver metastases after extensive partial hepatectomy. Utilizing this murine HCC metastasis model, we investigated the antitumor activity of both remnant liver and exogenously transferred NK cells.
The anti-HCC activity of liver NK cells significantly decreased after partial hepatectomy. The expression of CD69 and tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) on liver NK cells was temporarily downregulated. The adoptive transfer of NK cells, including a TRAIL-expressing fraction, extracted from the liver perfusates of poly I:C-stimulated B6 mice inhibited the growth of liver metastasis in B6 or (B6xBALB/c) F1 (B6CF1) mice that underwent hepatectomy and received intraportal Hepa1-6 injection.
These findings indicate that adoptive immunotherapy using activated NK cells extracted from normal liver perfusates may be a novel technique for reconstituting the depressed immune status in cases of living donor liver transplantation involving HCC patients, recipients of a partial liver graft.
据报道,部分肝切除术后肝脏自然杀伤(NK)细胞的抗肿瘤活性会降低,这表明免疫状态如此低下的患者易患肝细胞癌(HCC)复发。我们推测,使用活化的NK细胞进行过继性免疫治疗可能是改善肝切除术后或部分肝移植后HCC患者免疫状态低下的一种新策略。在本研究中,我们通过使用小鼠模型验证了这一假设。
门静脉内注射1 - 5×10⁶个Hepa1-6细胞(肝癌细胞系)在未处理的B6小鼠中未导致肝转移,但在广泛的部分肝切除术后导致肝转移灶生长。利用这种小鼠HCC转移模型,我们研究了残余肝脏和外源性转移的NK细胞的抗肿瘤活性。
部分肝切除术后肝脏NK细胞的抗HCC活性显著降低。肝脏NK细胞上CD69和肿瘤坏死因子(TNF)相关凋亡诱导配体(TRAIL)的表达暂时下调。从聚肌胞苷酸(poly I:C)刺激的B6小鼠肝脏灌流液中提取的包括表达TRAIL部分的NK细胞过继性转移,抑制了接受肝切除术并门静脉内注射Hepa1-6的B6或(B6×BALB/c)F1(B6CF1)小鼠肝转移灶的生长。
这些发现表明,使用从正常肝脏灌流液中提取的活化NK细胞进行过继性免疫治疗可能是一种在涉及HCC患者的活体供肝移植(部分肝移植受者)病例中重建免疫状态低下的新技术。